Psyence Biomedical (PBM) 6-KCurrent report (foreign)

Filed: 23 Oct 24, 4:01pm

Free signup for more

Track your favorite companies
Receive email alerts for new filings
Personalized dashboard of news and more
Access all data and search results

Search this filing

All

Tables only

Footnotes only

Pre-defined:

Table of contents

Filing tables

Export all tables to Excel

Filing exhibits

6-K Current report (foreign)
99.1 Exhibit 99.1
99.2 Exhibit 99.2
99.3 Exhibit 99.3

PBM similar filings

22 Nov 24 Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation
12 Nov 24 Current report (foreign)
1 Nov 24 Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabs
23 Oct 24 Current report (foreign)
8 Oct 24 Debt-for-equity Exchange Agreement
20 Sep 24 Share Purchase and Sale Agreement
13 Sep 24 Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq

Filing view

Default size S M L
Default font Times Arial

External links

View on EDGAR (sec.gov)

Share this filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2024

Commission File Number: 001-41937

Psyence Biomedical Ltd.

(Translation of registrant’s name into English)

121 Richmond Street West
Penthouse Suite 1300
Toronto, Ontario M5H 2K1

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

☒ Form 20-F ☐ Form 40-F

EXHIBIT INDEX

	Exhibit			Description
	99.1			Notice of Annual General and Special Meeting of Shareholders to be held on November 12, 2024 and Management Information Circular, including the Consolidated Financial Statements of the Company for the years ended March 31, 2024 and 2023, and the Management Discussion and Analysis related thereto, dated October 23, 2024.
	99.2			Notice of Meeting and Record Date
	99.3			Form of Proxy

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: October 23, 2024

Psyence Biomedical Ltd.

By:

/s/ Dr. Neil Maresky

Name: Dr. Neil Maresky
Title: Chief Executive Officer and Director

Resources

Knowledgebase
Log In
Register

Company

About
Contact
Solutions

Products

Deal Roadshow
DealVDR
Evercall
Finsight.com

CapEdge

Earnings Calendar
Earnings Transcripts
EDGAR Filing Screener
IPO Calendar

Compliance
Privacy
Security
Terms

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.